All News

liver.jpg

Increased Methotrexate Liver Disease in Psoriasis

Jack Cush, MD

A Danish cohort study examined the risk of methotrexate related liver disease risk in patients with psoriasis (PsO)and psoriatic arthritis (PsA), and found that compared to rheumatoid arthritis (RA), psoriatic patients had up to a 3 fold higher risk of liver disease. 

Read Article
RheumNow Podcast square

RheumNow Podcast – Combination Biologics

Jack Cush, MD

Dr. Jack Cush serves up this week's news and articles from RheumNow.com.

Read Article
COVID19.needles.Rx_.jpg

Reactogenicity Following mRNA COVID-19 Vaccines

Jack Cush, MD

JAMA has published the real-world reporting of mRNA vaccine side effects (reactogenicity) gathered from CDC V-safe Surveillance system and shows that local and systemic reactions were often mild and transient and most commonly seen during the first day following their second dose.

Read Article
RheumNow Podcast square

RheumNow Podcast – Upadacitinib Wins in PsA (4.2.2021)

Jack Cush, MD

Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.

Read Article
pregnant.baby_.hands_.jpg

Safety of Paternal DMARD or Biologic Use

Jack Cush, MD

A large cohort study of expectant fathers treated for immune-mediated inflammatory diseases (IMIDs) failed to show any detrimental effect from paternal exposure to immunosuppressive or biologic agents on offspring outcomes.

Read Article
Liver.hepatitis.jpg

Liver Management in Rheumatoid Arthritis - RNL2021 Highlight

Olga Petryna, MD

While rheumatoid arthritis (RA) is not known to affect the liver directly, underlying liver disease and treatment-related effects on the liver can often become an obstacle in the management of many RA patients. In his Sunday presentation at RNL2021, Dr.

Read Article
colitis.jpg

Low IBD Risk with IL-17 Inhibition

Jack Cush, MD

Incident or worsening colitis is a rare complication of IL-17 inhibitor therapy; a real world study confirms very low rates of new IBD in patients starting secukinumab.

Read Article
T%20cell.jpg

Checkpoint Inhibitor Use with Pre-existing Autoimmune Disease

Jack Cush, MD

Annals of Internal Medicine reports treating advanced melanoma with immune checkpoint inhibitors (ICI) in patients with pre-existing autoimmune disease (AID) was as effective and safe in those with AID compared to those without AID, although severe colitis occurred more frequently among pati

Read Article
Metanalysis of IBD studies finds combo biologics may have efficacy in refractor IBD. 279 IBD pts Rx w/ dual biologic or JAKi Rx . Most common = TNFi + anti-integrins (48%), ustekinumab & integrins (19%); remission seen in 59% & 34%, higher w/ EIM https://t.co/RReyRuNXck

Links:

Dr. John Cush RheumNow ( View Tweet)

Liver Management in RA - #RNL2021 Highlight by @DrPetryna While RA is not known to affect the liver directly, underlying liver disease and treatment-related effects on the liver can often become an obstacle in the mgmt of many RA patients. https://t.co/OeuloDIXMF

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Liver Management in Rheumatoid Arthritis - #RNL2021 Highlight by Dr. Olga Petryna ( @DrPetryna ) https://t.co/OeuloE0yEd https://t.co/qYd1K0dADu

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: Low IBD Risk with IL-17 Inhibition https://t.co/1kUH7sP755 https://t.co/DypPAcxB2a

Links:

Dr. John Cush RheumNow ( View Tweet)
Italian IBD clinic with 90 IBD Vedolizumab Tx pts, 8%(11) developed severe enthesitis (4 Multifocal, 6 unifocal). Sxs after mean 46 wks, CRP=5.1 mg/dl, majority HLA-B27 negative; confirmed by PD/UA in 7 - 4/7 developed post-inflam entheseal calcifications https://t.co/uwAJM8giBX

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr Uma Mahadevan presents results of the 14 yr registry study of pregnancy in IBD (Crohn's &UC) 1431 pts on with no Rx, thiopurines, biologics or thiop+biologics, showed no rush of fetal malformation, but did have incr in spont abortions @RWCSmtg @UmaMahadevanIBD https://t.co/SVQ2q1mJNW
Dr. John Cush RheumNow ( View Tweet)
Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA The FDA has notified healthcare professionals of a safety alert concerning tofacitinib (Xeljanz) when given to at-risk rheumatoid arthritis patients. https://t.co/RJD8CMouHK https://t.co/bipwWlIhiB

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 3 cross-sectional & 2case-control studies shows that the risk of developing #RA is elevated in patients with Crohns colitis (RR = 3.14; 95% CI: 2.46–4.01) and ulcerative colitis (RR = 2.29; 95% CI: 1.76–2.97) https://t.co/TIpd6lh5IZ

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Clinic - When RA Meets UC Ulcerative Colitis is complicating RA therapy https://t.co/a0LPvqPe1t

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Clinic - Arthritis and Colitis https://t.co/U5NrQuIcrd https://t.co/LbuRy9pTIl

Links:

Dr. John Cush RheumNow ( View Tweet)
Ehlers-Danlos Syndrome pts have higher association with GI conditions (IBS, etc OR =3.57), POTS & Autonomic dysfunction (OR=4.4), food allergy (OR= 3.9), CV complications (OR 6.1; MV dx, aortic aneurysm), longer hospitalizations (OR= 1.76) https://t.co/noobvrx0cQ

Links:

Dr. John Cush RheumNow ( View Tweet)

UTSW Rheum Grand Rounds - IgG4 Dz commonly presents as major salivary and lacrimal gland enlargement, orbital disease, autoimmune pancreatitis, retroperitoneal (mass) fibrosis or tubulointerstitial nephritis. @UTSWIMchief

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×